Ironwood Pharmaceuticals stock gains 5.52 percent to EUR 3.25

Published on 10/20/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven analysts set USD 6.23 on October 13, 2026. Ironwood Pharmaceuticals stock costs EUR 3.25 on October 20, 2026, up 5.52 percent versus Xetra close.

Price and analyst facts

Seven analysts set a USD 6.23 average target on October 13, 2026.
Ironwood Pharmaceuticals stock had a 52-week range of USD 1.47 to USD 5.78 as of October 20, 2026.
Ironwood Pharmaceuticals stock costs EUR 3.25 at Lang & Schwarz on October 20, 2026 at 6:47 p.m. CEST, 5.52 percent above the Xetra close of October 19, 2026.
Market capitalization stood at USD 603.3 million on October 20, 2026.

IRWD, US46333X1081, Illustration mit AI erstellt.

Ironwood Pharmaceuticals stock traded at EUR 3.25 at Lang & Schwarz on October 20, 2026 at 6:47 p.m. CEST, 5.52 percent above the Xetra close of October 19, 2026. The sharpest investor reference is the current analyst view, with seven firms carrying an average 12-month target of USD 6.23, according to MarketBeat on October 13, 2026.

Analyst target stays above the stock

The USD 6.23 average target is materially above the latest Nasdaq quotation of USD 3.65 at 4:57 p.m. ET on October 20, 2026. Using those two prices, the target lies 70.68 percent above the US share price. MarketBeat described the consensus as Moderate Buy, based on seven analysts, including four hold ratings, two buy ratings and one strong buy rating.

The target spread is wide. MarketBeat listed a low target of USD 3.70 and a high target of USD 10.00, putting the current US share price below both the average and high cases while sitting just below the low target. The range signals that the analyst view is not uniform even though the average remains above the quotation.

Price position and valuation

Ironwood Pharmaceuticals had a 52-week range of USD 1.47 to USD 5.78 as of October 20, 2026. The Nasdaq price of USD 3.65 was 36.85 percent below the yearly high and 148.30 percent above the yearly low. The stock traded within that range while volume reached 757,911 shares and market capitalization stood at USD 603.3 million.

The company is a Boston-based biotechnology business focused on gastrointestinal and rare diseases. Its commercial portfolio includes LINZESS, while apraglutide is being developed for short bowel syndrome. Ironwood identifies itself as Nasdaq-listed under the symbol IRWD on its investor-relations page, which also describes the company's collaboration-led commercial model through Ironwood Pharmaceuticals.

What does the price move change?

The euro quotation gained 5.52 percent against the Xetra close, placing the German trading indication above EUR 3.00 after the Xetra session ended. That move is larger than the gap between the current US price and the low analyst target, but the target comparison remains the clearer valuation reference because it uses the same US currency on both sides.

Stock price and investor perspective

For investors, the central contrast is a strong one-day euro move against a share price still 36.85 percent below its 52-week high. The USD 6.23 average target supplies a dated benchmark, while Ironwood's GI-focused portfolio gives the stock its business identity.

Ironwood Pharmaceuticals stock was trading at EUR 3.25 at Lang & Schwarz on October 20, 2026 at 6:47 p.m. CEST, 5.52 percent above the Xetra close of October 19, 2026 at EUR 3.08. The further course of trading is shown by the continuously updated real-time quote of Ironwood Pharmaceuticals stock.